title: Employment of the Triple Helix concept for development of regenerative medicine applications based on human pluripotent stem cells.
abstract: Using human pluripotent stem cells as a source to generate differentiated progenies for regenerative medicine applications has attracted substantial interest during recent years. Having the capability to produce large quantities of human cells that can replace damaged tissue due to disease or injury opens novel avenues for relieving symptoms and also potentially offers cures for many severe human diseases. Although tremendous advancements have been made, there is still much research and development left before human pluripotent stem cell derived products can be made available for cell therapy applications. In order to speed up the development processes, we argue strongly in favor of cross-disciplinary collaborative efforts which have many advantages, especially in a relatively new field such as regenerative medicine based on human pluripotent stem cells. In this review, we aim to illustrate how some of the hurdles for bringing human pluripotent stem cell derivatives from bench-to-bed can be effectively addressed through the establishment of collaborative programs involving academic institutions, biotech industries, and pharmaceutical companies. By taking advantage of the strengths from each organization, innovation and productivity can be maximized from a resource perspective and thus, the chances of successfully bringing novel regenerative medicine treatment options to patients increase.
authors.affiliation: Cellectis AB, Arvid Wallgrens Backe 20, 413 46 Göteborg, Sweden ; Systems Biology Research Center, School of Bioscience, University of Skövde, 541 28 Skövde, Sweden.
authors.forename: Peter
authors.initials: P
authors.lastname: Sartipy
authors.affiliation: Cellectis AB, Arvid Wallgrens Backe 20, 413 46 Göteborg, Sweden ; Current address: NovaHep AB, Arvid Wallgrens Backe 20, 413 46 Göteborg, Sweden.
authors.forename: Petter
authors.initials: P
authors.lastname: Björquist
keywords: Clinical applications; Human pluripotent stem cells; Regenerative medicine